PROCEPT BioRobotics (NASDAQ:PRCT) used its 2026 Analyst Day to outline what management characterized as a large, underpenetrated opportunity in benign prostatic hyperplasia (BPH), a developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results